Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Chiang, Kun Chun ^a   Tsui, Ke Hung ^a,b   Chung, Li Chuan ^b   Yeh, Chun Nan ^a   Chang, Phei Lang ^a,b   Chen, Wen Tsung ^c   Juang, Horng Heng ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL KAOHSIUNG UNIVERSITY OF HOSPITALITY AND TOURISM   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAMPTOTHECIN; DOXORUBICIN; PIFITHRIN ALPHA; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; ANTINEOPLASTIC AGENT; BTG2 PROTEIN, HUMAN; DNA TOPOISOMERASE INHIBITOR; IMMEDIATE EARLY PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; BTG2 GENE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; NONHUMAN; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION; UPREGULATION; CELL CYCLE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; MALE; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOPOISOMERASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84895864941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089117     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565. (Pubitemid 32916759)
3. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573. (Pubitemid 35402960)
4. Zaorsky NG, Trabulsi EJ, Lin J, Den RB (2013) Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin Oncol 40: 308-321.
5. Box VG (2007) The intercalation of DNA double helices with doxorubicin and nogalamycin. J Mol Graph Model 26: 14-19.
6. Tirone F (2001) The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol 187: 155-165.
7. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH (2008) Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 68: 610-619.
8. Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH (2012) Baseline prostate-specific antigen testing at a young age. Eur Urol 61: 1-7.
9. Tsui KH, Chang PL, Lin HT, Juang HH (2004) Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. J Urol 172: 2035-2039.
10. Bhattacharya S, Ray RM, Johnson LR (2009) Role of polyamines in p53- dependent apoptosis of intestinal epithelial cells. Cell Signal 21: 509-522.
11. Mizutani K, Matsumoto K, Hasegawa N, Deguchi T, Nozawa Y (2006) Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Exp Oncol 28: 209-215. (Pubitemid 44735911)
12. Tsui KH, Chung LC, Wang SW, Feng TH, Chang PL, et al. (2013) Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. J Mol Endocrinol 51: 131-141.
13. Juang HH, Chung LC, Sung HC, Feng TH, Lee YH, et al. (2013) Metallothionein 3: An androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. Prostate 73: 1495-1506.
14. Chung LC, Tsui KH, Feng TH, Lee SL, Chang PL, et al. (2012) L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells. Am J Physiol Cell Physiol 302: C676-685.
15. Tsui KH, Feng TH, Lin YF, Chang PL, Juang HH (2011) p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate 71: 62-70.
16. Tsui KH, Feng TH, Chung LC, Chao CH, Chang PL, et al. (2008) Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line. Anticancer Res 28: 1969-1976.
17. Tsui KH, Wu L, Chang PL, Hsieh ML, Juang HH (2004) Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. J Urol 172: 2029-2034. (Pubitemid 39363122)
18. Tsui KH, Chung LC, Feng TH, Chang PL, Juang HH (2012) Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. Int J Cancer 130: 2812-2823.
19. Sukhatme VP, Kartha S, Toback FG, Taub R, Hoover RG, et al. (1987) A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. Oncogene Res 1: 343-355. (Pubitemid 18046336)
20. Fletcher BS, Lim RW, Varnum BC, Kujubu DA, Koski RA, et al. (1991) Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J Biol Chem 266: 14511-14518. (Pubitemid 21907533)
21. Lim IK (2006) TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol 132: 417-426.
22. Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, et al. (1996) Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14: 482-486. (Pubitemid 26414597)
23. Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, et al. (2000) BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 27: 57-64. (Pubitemid 30090587)
24. Ryu MS, Lee MS, Hong JW, Hahn TR, Moon E, et al. (2004) TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res 299: 159-170. (Pubitemid 39078391)
25. Zhang L, Huang H, Wu K, Wang M, Wu B (2010) Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep 37: 2579-2586.
26. Elmore LW, Di X, Dumur C, Holt SE, Gewirtz DA (2005) Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 11: 2637-2643. (Pubitemid 40569464)
27. Hoffman KL, Lerner SP, Smith CL (2013) Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer 4: 24-35.
28. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, et al. (1999) Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5: 2082-2088. (Pubitemid 29399262)
29. Duriez C, Falette N, Audoynaud C, Moyret-Lalle C, Bensaad K, et al. (2002) The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene 282: 207-214. (Pubitemid 34117577)
30. Sasajima H, Nakagawa K, Yokosawa H (2002) Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. Eur J Biochem 269: 3596-3604. (Pubitemid 34989004)
31. Lawrence MG, Lai J, Clements JA (2010) Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 31: 407-446.
32. Fitzpatrick JM, Banu E, Oudard S (2009) Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 103: 578-587.
33. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, et al. (2008) Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 68: 7110-7119.
34. Vukmirovic-Popovic S, Escott NG, Duivenvoorden WC (2008) Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples. Oncol Rep 20: 897-903.
35. Kim J, Coetzee GA (2004) Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93: 233-241. (Pubitemid 44264201)
36. Chen CD, Sawyers CL (2002) NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22: 2862-2870. (Pubitemid 34263006)
37. Tsui KH, Lin YF, Chen YH, Chang PL, Juang HH (2011) Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells. J Androl 32: 383-393.